These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8549387)

  • 21. [The use of levofloxacin for the empirical treatment of exacerbations of mild, chronic COPD: Is it justified in under-65-years-old patients with no comorbidity?].
    Roig J; Martínez Benazet J; Casal J
    Arch Bronconeumol; 2002 Nov; 38(11):547; author reply 547-8. PubMed ID: 12435323
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiresistant pulmonary infection in cystic fibrosis--prevention is better than cure.
    Smyth A
    Lancet; 2005 Aug 6-12; 366(9484):433-5. PubMed ID: 16084235
    [No Abstract]   [Full Text] [Related]  

  • 23. Causative organisms in acute exacerbation of chronic airways disease and response to ofloxacin therapy.
    Sufarlan AW; Zainudin BM; Pit S; Ishak I
    Drugs; 1995; 49 Suppl 2():442-5. PubMed ID: 8549394
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
    Scheen AJ
    Rev Med Liege; 2000 Nov; 55(11):1015-7. PubMed ID: 11195704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R; Andrews JM
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.
    Azoicai D; Antoniu SA
    Expert Opin Investig Drugs; 2013 Feb; 22(2):267-76. PubMed ID: 23176385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
    Watanabe K; Yoshida M; Ishibashi T; Yamada H; Kido M; Hirose T; Maeda F; Matsuzaki Y
    Drugs; 1995; 49 Suppl 2():448-50. PubMed ID: 8549396
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of quinolones in respiratory tract infections.
    Maesen FP; Davies BI; Geraedts WH; Baur C
    Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 65-year-old woman with acute cough illness and an important engagement.
    Gonzales R
    JAMA; 2003 May; 289(20):2701-8. PubMed ID: 12771117
    [No Abstract]   [Full Text] [Related]  

  • 30. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Sollet JP
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections.
    Sawae Y; Ninomiya K; Takaki K; Shimono N; Misumi H; Okada K
    Drugs; 1995; 49 Suppl 2():430-2. PubMed ID: 8549390
    [No Abstract]   [Full Text] [Related]  

  • 32. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections].
    Płusa T
    Pol Merkur Lekarski; 2011 Feb; 30(176):91-6. PubMed ID: 21544977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Levofloxacin for prevalent infections in primary care medicine].
    Redondo Sánchez J
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():29-33. PubMed ID: 10563108
    [No Abstract]   [Full Text] [Related]  

  • 35. Activity of levofloxacin, ofloxacin, D-ofloxacin and ciprofloxacin against systemic and respiratory tract infections in laboratory animals.
    Klesel N; Geweniger KH; Koletzki P; Isert D; Limbert M; Markus A; Riess G; Schramm H; Seibert G; Iyer P
    Drugs; 1995; 49 Suppl 2():211-4. PubMed ID: 8549307
    [No Abstract]   [Full Text] [Related]  

  • 36. New fluoroquinolone antibiotics.
    Drug Ther Bull; 1999 Jan; 37(1):6-8. PubMed ID: 10562769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The John Barnwell Lecture. The chemotherapy of bacterial respiratory infections.
    Crofton J
    Am Rev Respir Dis; 1970 Jun; 101(6):841-59. PubMed ID: 4914352
    [No Abstract]   [Full Text] [Related]  

  • 38. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.
    Liou JM; Lin JT; Chang CY; Chen MJ; Cheng TY; Lee YC; Chen CC; Sheng WH; Wang HP; Wu MS
    Gut; 2010 May; 59(5):572-8. PubMed ID: 20427390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Hutchinson J
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102064
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
    Brückner O; Trautmann M
    J Chemother; 1989 Jul; 1(4 Suppl):782-3. PubMed ID: 16312637
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.